Hope Bancorp (HOPE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Capricor Therapeutics maintains a "Hold" rating despite positive phase 3 HOPE-3 results for Deramiocel in DMD cardiomyopathy. HOPE-3 met both primary [PUL v2.0] and key secondary [LVEF] endpoints, aligning with FDA's requirements for potential BLA resubmission of Deramiocel. Regulatory uncertainty remains, particularly regarding CMC issues and whether or not HOPE-3 fully satisfies FDA approval criteria.
Hope Bancorp, Inc. (NASDAQ:HOPE ) Q3 2025 Earnings Call October 28, 2025 12:30 PM EDT Company Participants Maxime Olivan Kevin Kim - Chairman, President & CEO Julianna Balicka - Executive VP & CFO Peter Koh - Senior EVP & COO Conference Call Participants Matthew Clark - Piper Sandler & Co., Research Division Gary Tenner - D.A. Davidson & Co., Research Division Kelly Motta - Keefe, Bruyette, & Woods, Inc., Research Division Timothy Coffey - Janney Montgomery Scott LLC, Research Division Presentation Operator Good day, and welcome to the Hope Bancorp 2025 Third Quarter Earnings Conference Call.
Although the revenue and EPS for Hope Bancorp (HOPE) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Hope Bancorp (HOPE) came out with quarterly earnings of $0.25 per share, missing the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.21 per share a year ago.
Hope Bancorp, Inc. (NASDAQ:HOPE ) Q2 2025 Earnings Conference Call July 22, 2025 12:30 PM ET Company Participants Angie Yang - Senior VP and Director of IR & Corporate Communications Kevin Kim - Chairman, President & CEO Julianna Balicka - Executive VP & CFO Peter Koh - Senior EVP & COO Conference Call Participants Matthew Clark - Piper Sandler & Co., Research Division Gary Tenner - D.A. Davidson & Co., Research Division Kelly Motta - Keefe, Bruyette, & Woods, Inc., Research Division Timothy Coffey - Janney Montgomery Scott LLC, Research Division Operator Good day, and welcome to the Hope Bancorp 2025 Second Quarter Earnings Conference Call.
Although the revenue and EPS for Hope Bancorp (HOPE) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Hope Bancorp (HOPE) came out with quarterly earnings of $0.19 per share, missing the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.22 per share a year ago.
Hope Bancorp (HOPE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Hope Bancorp (HOPE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Capricor Therapeutics's dip caused by the Complete Response Letter is a buying opportunity considering the readout of HOPE-3 within 2-3 months. Based on HOPE-2 data and the expected course of Duchenne muscular dystrophy cardiomyopathy, I estimate a very high probability of a positive readout in HOPE-3, at least for cardiac endpoints. CAPR remains well funded through approval, not accounting for milestone payments, future royalty revenue, and a potential Priority Review Voucher worth $150M.
Hope Bancorp, Inc. (NASDAQ:HOPE ) Q1 2025 Earnings Conference Call April 22, 2025 12:30 PM ET Company Participants Angie Yang - IR Kevin Kim - Chairman, President and CEO Julianna Balicka - CFO Peter Koh - COO Conference Call Participants Andrew Leischner - KBW Ahmad Hasan - D.A. Davidson Operator Good day, and welcome to the Hope Bancorp 2025 First Quarter Earnings Conference Call.